基于生物信息学分析鉴定肝细胞癌预后生物标志物

摘要/Abstract

摘要： 目的运用生物信息学方法筛选出新的肝细胞癌(HCC)预后生物标志物。方法通过GEO2R筛选GSE14520数据集中的差异表达基因(DEG),利用STRING构建蛋白互作网络(PPI),Cytoscape软件筛选出关键基因。DAVID进行GO和KEGG分析,然后使用GEPIA分析关键基因在HCC中的表达以及与预后的关系。结果 GSE14520数据集共筛选出348个差异表达基因,其中91个上调基因,257个下调基因。从PPI中筛选出排列最前的2个网络模块:模块1和模块2。两个模块中位于网络中心区域的关键基因共46个。关键基因显著富集于细胞周期、DNA复制药物代谢等信号通路。GEPIA验证显示关键基因中的PROZ和F9在HCC患者中显著低表达,并与患者总体生存率及无病生存率降低相关。结论 PROZ和F9可作为HCC的潜在预后生物标志物。

关键词: 肝细胞癌, DEGs, 生物信息学分析

Abstract: Objective To investigate new prognostic biomarkers of hepatocellular carcinoma (HCC) through bioinformatics.Methods The differentially expressed genes (DEGs) in the GSE14520 data set were screened by GEO2R, a protein-protein interaction (PPI) network was constructed by STRING, and key genes were screened out by Cytoscape software. GO and KEGG analyses were performed in DAVID database. Then GEPIA was used to analyze the expression levels of key genes in HCC and their relationship with prognosis.Results A total of 348 DEGs were screened out, including 91 up-regulated genes and 257 down-regulated genes. The top 2 network modules were screen out from the PPI: module 1 and module 2. There were 46 key genes in the center area of the network in the 2 modules. Key genes were significantly enriched in signaling pathways such as cell cycle, DNA replication and drug metabolism. It was verified by GEPIA that PROZ and F9 were significantly under-expressed in HCC patients, and were associated with a decrease in the overall survival rate and disease-free survival rate of HCC patients.Conclusion PROZ and F9 can be regarded as potential prognostic biomarkers for HCC.

Key words: Hepatocellular carcinoma, Differentially expressed genes, Bioinformatics analysis

何春梅, 莫之婧. 基于生物信息学分析鉴定肝细胞癌预后生物标志物[J]. 肝脏, 2021, 26(5): 522-526.

HE Chun-mei, MO Zhi-jing. Prognostic biomarkers of hepatocellular carcinoma identified by bioinformatics[J]. Chinese Hepatolgy, 2021, 26(5): 522-526.

参考文献

[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394: 1145-1158.
[2] Benson AB 3rd, D'Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw, 2017, 15: 563-573.
[3] Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: what role do they play (If any) for diagnosis, prognosis and tumor response prediction for hepatocellular carcinoma?. Dig Dis Sci, 2019, 64: 918-927.
[4] Zhao H, Yi B, Liang Z, et al. Cyclin G2, a novel target of sulindac to in hibit cell cycle progression in colorectal cancer. Gen Dis, 2021, 8.
[5] Zhou J, Han S, Qian W, et al. Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. 2018, 11: 4451-4459.
[6] Jin J, Xu H, Li W, et al. LINC00346 acts as a competing endogenous RNA regulating development of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. Front Bioeng Biotechnol, 2020, 8: 54.
[7] Deng J, Wang ES, Jenkins RW, et al. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer Discov, 2017, 8:216-233.
[8] Meng J, Liu HL, Ma D, et al. Upregulation of aurora kinase A promotes vascular smooth muscle cell proliferation and migration by activating the GSK-3β/β-catenin pathway in aortic-dissecting aneurysms. Life Sci, 2020: 118491.
[9] 马向明,侯婧悦,付庆江,等. 线粒体丙酮酸载体在肝细胞癌中的表达及临床意义.肝脏, 2020, 25: 573-577.
[10] Avadhanula S, Introne WJ, Auh S, et al. Assessment of thyroid function in patients with alkaptonuria. JAMA Netw Open, 2020, 3: e201357.
[11] Hughes JH, Liu K, Plagge A, et al. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria. Hum Mol Genet, 2019, 28: 3928-3939.
[12] Zatkova A, Ranganath L, Kadasi L. Alkaptonuria: current perspectives. Appl Clin Genet, 2020, 13: 37-47.
[13] Berg M, Polyzos KA, Agardh H, et al. 3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in Ldlr-/- mice. Cardiovasc Res, 2020, 116: 1948-1957.
[14] Krooss S, Werwitzke S, Kopp J, et al. Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B. PLoS Genet, 2020, 16: e1008690.
[15] Kloek AT, Khan HN, Valls Seron M, et al. Variation in coagulation and fibrinolysis genes evaluated for their contribution to cerebrovascular complications in adults with bacterial meningitis in the Netherlands. J Infect, 2018, 77: 54-59.
[16] Xu Z, Zhang Y, Liu W, et al. Polymorphisms of F2, PROC, PROZ, and F13A1 genes are associated with recurrent spontaneous abortion in Chinese han women. Clin Appl Thromb Hemost, 2018, 24: 894-900.
[17] Salloum-Asfar S, Arroyo AB, Teruel-Montoya R, et al. MiRNA-based regulation of hemostatic factors through hepatic nuclear factor-4 alpha. PLoS One, 2016, 11: e0154751.